- Resource
- BR1DGE
- Early Detection
- Video
Communicating the Benefits of T1D Screening and Early Detection
Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.
Learning Objectives
- Recognize the importance of effective communication about islet autoantibody screening with different audiences, including individuals with or without a personal connection to T1D, clinicians, and healthcare decision-makers
- Explain the rationale and evidence for early T1D detection, including reduced risk of DKA, access to research studies, and time to receive diabetes education before the onset of Stage 3 T1D
Summary
This video examines how to effectively communicate about islet autoantibody screening for type 1 diabetes (T1D) with individuals and families considering screening, and healthcare teams implementing early T1D detection pathways. Jaivir Pall explores common questions about screening and what happens next, and stresses the importance of adapting conversations to people’s lived experience. Prof Chantal Mathieu highlights the key benefits of T1D screening, including reduced risk of diabetic ketoacidosis through education and monitoring, access to research opportunities, and a softer landing to Stage 3 T1D. Prof Anette-Gabriele Ziegler reflects on the early experiences of the Fr1da program.
MAT-GLB-2601301 - 1.0 - 08/2026
Faculty Disclosures
Jaivir Pall
- Speaker/Consultant: Sanofi, AbbVie
- Other: Eli Lilly and Company, Novo Nordisk, Dexcom, Minimed, Boehringer Ingelheim, Roche, Zubi Capital Diabetes-Immune, Fund I, Abvance Therapeutics, Ancilia Biosciences, Viven Therapeutics, Zya Enzymes, Zubi Group, Luna Life Limited, Unison Bio, BioSapien and Harbr Ventures Fund
Prof Chantal Mathieu
- Research funding: Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics
- Speaker/Consultant: Sanofi
- Other: Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion, and Vertex
Prof Anette-Gabriele Ziegler
- Speaker/Consultant: The Leona M. and Harry B. Helmsley Charitable Trust, Sanofi France
- Other: Received honoraria from Georg Thieme Verlag, Novo Nordisk Norway, and Deutsche Diabetes Gesellschaft; support for attending meetings from Sanofi France; member of data monitoring committees for Provention Bio, Sanofi, Sanofi US Services, and ITB-Med; advisory board member for Sanofi France and Sanofi-Aventis US
The Evolving Landscape of Early Detection in T1D
Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.
Identifying Adult-onset T1D
Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.
Advancing Models of Care for People with Type 1 Diabetes
Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.